Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Sum­it­o­mo and Ot­su­ka’s schiz­o­phre­nia can­di­date ulotaront failed its Phase III test, with the com­pa­nies say­ing that the Covid-19 pan­dem­ic pushed the place­bo ef­fect to high­er-than-ex­pect­ed lev­els.

Al­though a place­bo ef­fect is gen­er­al­ly an­tic­i­pat­ed to blur psy­chi­atric tri­al re­sults, pre­lim­i­nary da­ta from a pair of Phase III tri­als, DI­A­MOND 1 and 2, sug­gest­ed place­bo may have “masked the ther­a­peu­tic ef­fect” of ulotaront, ac­cord­ing to the com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER